Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ACTR087 |
Trade Name | |
Synonyms | ACTR-087|ACTR 087 |
Drug Descriptions |
ACTR087 is a chimeric construct consisting of the extracellular domain of CD16 linked to CD3zeta signaling and 41BB co-stimulatory domains delivered into human T-cells via gamma-retrovirus, which may lead to enhanced anti-tumor activity in combination with tumor-targeting antibodies (Blood 2016, 128(22):3512). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C129715 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ACTR087 | ACTR087 | 0 | 0 |
ACTR087 + Rituximab | ACTR087 Rituximab | 0 | 1 |
ACTR087 + SEA-BCMA | ACTR087 SEA-BCMA | 0 | 1 |
ACTR087 + Trastuzumab | ACTR087 Trastuzumab | 0 | 1 |